ClinicalTrials.gov
public full text
Public Domain
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
This is an interventional, parallel arm assignment treatment study in individuals with Major Depressive Disorder (MDD). Each individual will be treated with a single dose of pimavanserin or placebo plus a single dose of psilocybin. Evaluations will be taken before dosing and following dosing at several timepoints up to 5 weeks post-dosing.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effect of SSRIs on Response to Psilocybin Therapy#878096
- Psilocybin for Major Depressive Disorder (MDD)#1165210
- PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)#1094826
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder#1058862
- Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder#871882
Record · ID 906047
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive